golden empire jili download
Why You Shouldn’t Miss Out On This Crypto If You Missed Dogecoin (DOGE) and Cardano (ADA)Godzilla and King Kong surely weren't born big. They began small and grew over time to their gargantuan sizes even if the movies don't tell their childhood stories. Likewise, huge companies of today were once much smaller (unless perhaps they were spin-offs). Investors who spotted them early had opportunities to make fortunes. Are You Missing The Morning Scoop? Wake up with Breakfast news in your inbox every market day. Sign Up For Free » Can you still find such monsters in the making? Three Motley Fool contributors think so. Here's why they think biotech stocks CRISPR Therapeutics (NASDAQ: CRSP) , Summit Therapeutics (NASDAQ: SMMT) , and Viking Therapeutics (NASDAQ: VKTX) could become much larger. An underrated stock with two approvals under its belt David Jagielski (CRISPR Therapeutics): If you're looking for stocks with mammoth upside, you might be tempted to look for risky stocks that don't have any approved drugs or treatments yet. But with CRISPR Therapeutics, you already have a stock that has an approved treatment -- it simply isn't far along in its rollout. In December 2023, regulators approved Casgevy, which is a gene-editing therapy the company has been developing with Vertex Pharmaceuticals . It was approved as a treatment for sickle cell disease for patients 12 years and older. Then, a month later, it was also approved to treat people with transfusion-dependent beta-thalassemia (for the same age group). Casgevy can be a game changer for patients with these rare blood disorders as it is a one-time functional cure. CRISPR will share in the profits with Vertex on Casgevy (collecting 40% of them), which could potentially help the company get to profitability. Currently, its operations are well funded with CRISPR reporting more than $1.9 billion in cash and marketable securities as of the end of September. For a business that has burned through $92.7 million in cash over the past nine months, that can provide it with a lot of runway and time to grow its operations and work on other treatments in its pipeline. At a modest market cap of just $4 billion, there's a lot of room for CRISPR to get a whole lot more valuable in the future as it scales its operations and Casgevy starts to generate revenue. Buying the healthcare stock now can be a great move for long-term investors. Already showing monster potential Keith Speights (Summit Therapeutics): It's practically unheard of for a company with no product on the market to have a market cap of $14 billion. But Summit Therapeutics is no ordinary company. The drugmaker in-licensed cancer immunotherapy ivonescimab in January 2023. That has turned out to be a brilliant move in retrospect. Earlier this year, Akeso (which originally developed ivonescimab) announced the drug beat Merck 's blockbuster immunotherapy Keytruda in a head-to-head late-stage study targeting non-small cell lung cancer (NSCLC). How big of a deal was this news? Consider that Keytruda was the world's best-selling drug last year, raking in sales of around $25 billion. Summit owns the commercial rights in the U.S., Canada, and Europe of a cancer immunotherapy that could be even more powerful than Keytruda. Granted, Summit can't ride on the clinical success achieved by Akeso. The company must conduct its own clinical studies to hopefully win approval for ivonescimab in the U.S. and elsewhere. However, that's exactly what it's doing with initial results expected from a late-stage study of the immunotherapy as a second-line treatment for NSCLC in mid-2025. Summit is also evaluating ivonescimab in another late-stage trial as a first-line treatment for NSCLC. Wall Street's consensus is that Summit's share price could soar more than 40% over the next 12 months. I'm not sure if this price target will be achieved, but it wouldn't surprise me if that's an overly pessimistic goal assuming the company announces positive clinical results next year. Summit Therapeutics is already showing monster potential. I suspect it will fulfill that potential if ivonescimab wins U.S. regulatory approval. You can still get in on the ground floor Prosper Junior Bakiny (Viking Therapeutics): Weight-loss management is the hottest therapeutic area in the pharmaceutical industry right now. Although the companies dominating the field are the usual suspects, a notable mid-cap biotech called Viking Therapeutics is looking to make waves in this market. Viking's lead anti-obesity candidate, VK2735, reported excellent results in phase 2 studies. It might still be a few years until VK2735 earns regulatory approval, but Viking Therapeutics is not a one-trick pony. The company is working on an oral version of VK2735 -- something many patients would choose over the weekly injections the original formulation comes with. Furthermore, Viking Therapeutics has another promising weight-loss candidate in preclinical studies . And I have yet to mention the drugmaker's VK2809, an investigational medicine for metabolic dysfunction-associated steatohepatitis -- a liver disease with obesity as a risk factor -- and Viking's VK0214, an investigational therapy for a rare nervous system disease called X-linked adrenoleukodystrophy. Many smaller drugmakers tend to hyperfocus on a single medicine, a strategy that allows them to avoid spreading their resources thin. Viking Therapeutics, though, is taking a different approach. The company is showing signs of one of the most critical factors successful biotechs need: innovation. There are still risks involved here. Viking's late-stage studies for VK2735 could flop. However, the company is looking increasingly attractive. In a decade, it could join the ranks of highly successful drugmakers. It's not too late to get in on the ground floor. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and CRISPR Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $898,809 !* Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. See the 10 stocks » *Stock Advisor returns as of November 18, 2024 David Jagielski has no position in any of the stocks mentioned. Keith Speights has positions in Vertex Pharmaceuticals. Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics, Merck, Summit Therapeutics, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy . 3 Monster Stocks in the Making was originally published by The Motley Fool
FORMER President Bill Clinton has been rushed to the hospital, it has been confirmed. Clinton, 78, is undergoing medical tests at Georgetown University Medical Centre, his former deputy chief of staff has said. It is understood he has developed a fever, but the situation is "not an emergency". A spokesperson for Clinton wrote on social media: "President Clinton was admitted to Georgetown University Medical Center this afternoon for testing and observation after developing a fever. "He remains in good spirits and deeply appreciates the excellent care he is receiving." Clinton, a Democrat who served two terms as president from January 1993 until January 2001, addressed the Democratic National Convention in Chicago this summer. He campaigned ahead of November's election for the unsuccessful White House bid of Democratic Vice President Kamala Harris. In the years since Clinton left the White House, he's faced some health scares. In 2004, he underwent quadruple bypass surgery after experiencing prolonged chest pains and shortness of breath. Clinton returned to the hospital for surgery for a partially collapsed lung in 2005, and in 2010 he had a pair of stents implanted in a coronary artery. Clinton responded by embracing a largely vegan diet that saw him lose weight and report improved health. In 2021, the former president was hospitalized for six days in California while being treated for an infection that was unrelated to COVID-19, when the pandemic was still near its height. An aide to the former president said then that Clinton had a urological infection that spread to his bloodstream, but was on the mend and never went into septic shock, a potentially life-threatening condition. The aide said Clinton was in an intensive care section of the hospital at that time, but was not receiving ICU care. Earlier this year, Clinton shocked his supporters during his speech with his older appearance and hoarse voice on day three of the Democratic National Convention. Clinton spoke into the microphone with a dominant tone, his voice reverberating throughout the stadium. But despite the power in his voice, there was a hoarse, scratchy quality that for some viewers, was hard to ignore. Some wondered if Clinton was sick — when President Joe Biden had displayed a raspy voice at June's presidential debate against Trump, it turned out he had Covid . "Does Bill Clinton have Covid?" an X user asked. "Why tf does he sound like that?" Another person called it "jarring" to see Clinton, 78, in old age "with his voice weakened." "Bill Clinton does not sound good," a third person wrote. "Hasn't for a while, sounding older than he is, and he's not exactly young these days." The 42nd president addressed the convention to cast his support for Vice President Kamala Harris but his supporters were focused on the sound of his voice rather than his words. More to follow... For the latest news on this story, keep checking back at The U.S. Sun, your go-to destination for the best celebrity news, sports news, real-life stories, jaw-dropping pictures, and must-see videos . Like us on Facebook at TheSunUS and follow us on X at @TheUSSunThe dominance of Chinese table tennis is not only a testament to the talent of the players but also a reflection of the country's rich history and tradition in the sport. Table tennis, also known as ping pong, has a deep-rooted cultural significance in China, dating back to ancient times. The sport has captured the hearts of millions of Chinese fans and continues to be a source of national pride and identity.
Tragedy Strikes a Haitian Slum: 184 Killed in Gang Armed AttackNvidia Expresses Willingness to Answer Any Regulatory Questions and Demonstrates a Cooperative Attitude